• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concept treatment strategy.

作者信息

Shi Yaoping, Shi Donghua, Chi Jiachang, Cui Dan, Tang Xiaoyin, Lin Yan, Wang Siying, Li Zonghai, Jin Haojie, Zhai Bo

机构信息

Department of Interventional Oncology, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.

Shanghai Cancer Institute, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.

出版信息

Cancer Commun (Lond). 2023 Sep;43(9):1064-1068. doi: 10.1002/cac2.12472. Epub 2023 Jul 21.

DOI:10.1002/cac2.12472
PMID:37478283
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10508142/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7f7/10508142/608dd0eccd83/CAC2-43-1064-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7f7/10508142/608dd0eccd83/CAC2-43-1064-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7f7/10508142/608dd0eccd83/CAC2-43-1064-g001.jpg

相似文献

1
Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concept treatment strategy.晚期肝细胞癌的局部治疗联合CAR-GPC3 T细胞疗法：一种概念验证性治疗策略。
Cancer Commun (Lond). 2023 Sep;43(9):1064-1068. doi: 10.1002/cac2.12472. Epub 2023 Jul 21.
2
Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.索拉非尼联合 GPC3-CAR T 细胞对肝癌小鼠模型的抗肿瘤作用。
Mol Ther. 2019 Aug 7;27(8):1483-1494. doi: 10.1016/j.ymthe.2019.04.020. Epub 2019 Apr 29.
3
Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma.装甲诱导型白细胞介素-12 增强了针对磷脂酰聚糖-3 的嵌合抗原受体工程 T 细胞在肝细胞癌中的抗肿瘤活性。
J Immunol. 2019 Jul 1;203(1):198-207. doi: 10.4049/jimmunol.1800033. Epub 2019 May 29.
4
Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials.嵌合抗原受体-磷脂酰肌醇蛋白聚糖-3 T细胞疗法治疗晚期肝细胞癌：I期试验结果
Clin Cancer Res. 2020 Aug 1;26(15):3979-3989. doi: 10.1158/1078-0432.CCR-19-3259. Epub 2020 May 5.
5
Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma.腺相关病毒-CCL19 和 GPC3 CAR-T 细胞联合治疗肝细胞癌。
J Immunol Res. 2021 Sep 3;2021:1782728. doi: 10.1155/2021/1782728. eCollection 2021.
6
Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.开发针对 GPC3 的嵌合抗原受体工程化自然杀伤细胞用于治疗肝细胞癌。
Mol Ther. 2018 Feb 7;26(2):366-378. doi: 10.1016/j.ymthe.2017.12.012. Epub 2017 Dec 19.
7
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.IL-7 和 CCL19 分泌型 CAR-T 细胞疗法治疗糖蛋白 3 或间皮素阳性肿瘤。
J Hematol Oncol. 2021 Jul 29;14(1):118. doi: 10.1186/s13045-021-01128-9.
8
Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma.非病毒 mcDNA 介导的双特异性 CAR T 细胞在肝癌实验小鼠模型中杀死肿瘤细胞。
BMC Cancer. 2022 Jul 25;22(1):814. doi: 10.1186/s12885-022-09861-1.
9
Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.靶向磷脂酰聚糖蛋白 3 的 T 细胞的开发用于治疗肝细胞癌。
Clin Cancer Res. 2014 Dec 15;20(24):6418-28. doi: 10.1158/1078-0432.CCR-14-1170. Epub 2014 Oct 15.
10
T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.经基因工程改造表达针对磷脂酰聚糖-3 的 T 细胞受体的 T 细胞在体外和小鼠中识别并杀伤肝癌细胞。
Gastroenterology. 2015 Oct;149(4):1042-52. doi: 10.1053/j.gastro.2015.05.055. Epub 2015 Jun 5.

引用本文的文献

1
Adoptive cell therapy for cancer: combination strategies and biomarkers.癌症的过继性细胞疗法：联合策略与生物标志物
Front Immunol. 2025 Aug 1;16:1603792. doi: 10.3389/fimmu.2025.1603792. eCollection 2025.
2
Advancing liver cancer treatment with dual-targeting CAR-T therapy.采用双靶点嵌合抗原受体T细胞（CAR-T）疗法推进肝癌治疗
J Nanobiotechnology. 2025 Jun 24;23(1):462. doi: 10.1186/s12951-025-03512-w.
3
Novel GPC3 N-terminal bispecific antibody exhibits dual anti-tumor effect against tumor cells.新型GPC3 N端双特异性抗体对肿瘤细胞具有双重抗肿瘤作用。

本文引用的文献

1
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours.CAR T 细胞杀伤需要 IFNγR 通路，但在实体瘤中而不是在液体肿瘤中。
Nature. 2022 Apr;604(7906):563-570. doi: 10.1038/s41586-022-04585-5. Epub 2022 Apr 13.
2
Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1.第三代 EphA2 CAR-T 细胞对胶质母细胞瘤的抗肿瘤活性与干扰素 γ 诱导的 PD-L1 有关。
Oncoimmunology. 2021 Aug 16;10(1):1960728. doi: 10.1080/2162402X.2021.1960728. eCollection 2021.
3
Navigating CAR-T cells through the solid-tumour microenvironment.
Invest New Drugs. 2025 May 1. doi: 10.1007/s10637-025-01530-x.
4
Spatial heterogeneity of the hepatocellular carcinoma microenvironment determines the efficacy of immunotherapy.肝细胞癌微环境的空间异质性决定免疫治疗的疗效。
Discov Oncol. 2025 Jan 7;16(1):15. doi: 10.1007/s12672-025-01747-5.
5
Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment.穿越肿瘤微环境的武装嵌合抗原受体T细胞的治疗靶点。
Exp Hematol Oncol. 2024 Sep 30;13(1):96. doi: 10.1186/s40164-024-00564-w.
6
Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment.开发用于癌症治疗的体内 CAR T 细胞疗法的进展和挑战。
EBioMedicine. 2024 Aug;106:105266. doi: 10.1016/j.ebiom.2024.105266. Epub 2024 Aug 1.
7
The Role of CD4T Cells in Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.CD4T 细胞在非酒精性脂肪性肝炎和肝细胞癌中的作用。
Int J Mol Sci. 2024 Jun 23;25(13):6895. doi: 10.3390/ijms25136895.
8
Current Advancements in Anti-Cancer Chimeric Antigen Receptor T Cell Immunotherapy and How Nanotechnology May Change the Game.当前癌症嵌合抗原受体 T 细胞免疫疗法的进展以及纳米技术如何改变游戏规则。
Int J Mol Sci. 2024 May 14;25(10):5361. doi: 10.3390/ijms25105361.
9
Atovaquone enhances antitumor efficacy of TCR-T therapy by augmentation of ROS-induced ferroptosis in hepatocellular carcinoma.阿托伐醌通过增强 ROS 诱导的肝癌铁死亡增强 TCR-T 治疗的抗肿瘤疗效。
Cancer Immunol Immunother. 2024 Feb 13;73(3):49. doi: 10.1007/s00262-024-03628-2.
CAR-T 细胞在实体瘤微环境中的行进。
Nat Rev Drug Discov. 2021 Jul;20(7):531-550. doi: 10.1038/s41573-021-00189-2. Epub 2021 May 10.
4
Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials.嵌合抗原受体-磷脂酰肌醇蛋白聚糖-3 T细胞疗法治疗晚期肝细胞癌：I期试验结果
Clin Cancer Res. 2020 Aug 1;26(15):3979-3989. doi: 10.1158/1078-0432.CCR-19-3259. Epub 2020 May 5.
5
Effectiveness and feasibility of external beam radiotherapy for hepatocellular carcinoma with inferior vena cava and/or right atrium involvement: a multicenter trial in Korea (KROG 17-10).韩国多中心试验（KROG 17-10）：外照射放疗治疗下腔静脉和/或右心房受累的肝细胞癌的疗效和可行性。
Int J Radiat Biol. 2020 Jun;96(6):759-766. doi: 10.1080/09553002.2020.1721607. Epub 2020 Feb 4.
6
Hypofractionated radiotherapy as a salvage treatment for recurrent hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: a multi-center analysis.大分割放疗作为下腔静脉/右心房肿瘤血栓复发性肝细胞癌的挽救性治疗：一项多中心分析。
BMC Cancer. 2019 Jul 5;19(1):668. doi: 10.1186/s12885-019-5870-3.
7
CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.实体瘤的嵌合抗原受体 T 细胞：在肿瘤微环境中寻找、浸润和存活的新策略。
Front Immunol. 2019 Feb 5;10:128. doi: 10.3389/fimmu.2019.00128. eCollection 2019.
8
CAR T cell immunotherapy for human cancer.嵌合抗原受体 T 细胞免疫疗法治疗人类癌症。
Science. 2018 Mar 23;359(6382):1361-1365. doi: 10.1126/science.aar6711.
9
Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey.肝切除术治疗伴有肝静脉侵犯的肝细胞癌：一项日本全国性调查。
Hepatology. 2017 Aug;66(2):510-517. doi: 10.1002/hep.29225. Epub 2017 Jun 26.